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Abstract: Pseudoxanthoma elasticum (PXE) is an inherited metabolic disease with autosomal
recessive inheritance caused by mutations in the ABCC6 gene. Since the first description of the disease
in 1896, alleging a disease involving the elastic fibers, the concept evolved with the further discoveries
of the pivotal role of ectopic mineralization that is preponderant in the elastin-rich tissues of the skin,
eyes and blood vessel walls. After discovery of the causative gene of the disease in 2000, the function
of the ABCC6 protein remains elusive. More than 300 mutations have been now reported and the
concept of a dermal disease has progressively evolved toward a metabolic disorder resulting from
the remote effects caused by lack of a circulating anti-mineralization factor. Very recently, evidence
has accumulated that this anti-mineralizing factor is inorganic pyrophosphate (PPi). This leads to
decreased PPi/Pi (inorganic phosphate) ratio that results from the lack of extracellular ATP release by
hepatocytes and probably renal cells harboring the mutant ABCC6 protein. However, the mechanism
by which ABCC6 dysfunction causes diminished ATP release remains an enigma. Studies of other
ABC transporters, such as ABCC7 or ABCC1 could help our understanding of what ABCC6 exact
function is. Data and a hypothesis on the possible roles of ABCC6 in acquired metabolic diseases are
also discussed.
Keywords: ABC transporter; inorganic pyrophosphate; pseudoxanthoma elasticum; arterial calcifications;
chronic kidney disease
1. Introduction
Membrane transporters are basic cellular elements, which play a central role in various cellular
functions and cells’ integrity. Adenosine triphosphate (ATP)-binding cassette (ABC) transporters are
a large family of 48 members involved in the pathogenesis of various inherited metabolic diseases.
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In this regard, ABCC6 is one of these new players, whose deficiency is responsible for pseudoxanthoma
elasticum (PXE), a rare and intriguing inherited disease with unexplained female 2 third prevalence
and whose phenotype is characterized by ectopic calcifications in elastin-rich tissues such as the
skin, the Burch’s membrane of the retina and the arterial wall. To date, the physiological role of
ABCC6 and its preferential substrate(s) remain an enigma. Recent findings are now showing a pivotal
role in the regulation of extracellular nucleotid metabolism and in the direct and remote control of
biomineralization. This review will summarize the current knowledge and speculated roles of ABCC6
transporter not only in PXE, but also in frequent acquired metabolic diseases characterized by arterial
calcifications (AC).
2. Pseudoxanthoma Elasticum: The Story of a “misnamed” Disease
The study of PXE, and thus the discovery of ABCC6, is paved by important clinical and scientific
rebounds. Thus a brief time-sketch of the progresses in our knowledge and on-going debates
are mandatory to the understanding of its biological and clinical relevance. PXE (also known
as Grönblad-Strandberg syndrome, elastosis dystrophica or elastodysplasia calcificans) is a rare
inherited disease (OMIM 264800, prevalence 1/25,000 to 1/50,000) characterized by a generalized
accumulation of calcified and fragmented elastic fibers selectively affecting the elastin-rich tissues
such as the skin, the retina and the vascular wall. Organs such as the kidneys, joints and tendons
are affected to various degrees, but remarkably, the pulmonary tissue seems to be spared in the
disease phenotype [1,2]. The skin manifestations are often the initial and most visible lesions in PXE,
with a “pseudoxanthoma” aspect affecting, for yet unknown reasons, the flexural areas of the body
(i.e., neck, arm, knee joints, groin) and periumbilical areas. The ambiguous name “pseudoxanthoma”
arose from the fact that the skin lesions mimic “xanthoma” lesions (i.e., subcutaneous papules of
yellow-orange color). Following the initial and independent reports on “xanthomas” lesion [3–5],
François-Ferdinand Darier in 1896 presented the idea that they were distinct from xanthomas with
an unusual involvement of elastic tissues, thereafter introducing the prefix “pseudo” as to cast doubt
on the real nature of the dermal lesions [6]. The fundamental histopathological feature of PXE,
i.e., the calcification of elastin, were described first in 1901 by von Tannenhain; Werther seemed to
have seeded the idea that PXE was a congenital trait [7]. Knapp was the first to report a specific
retinopathy coining the descriptor “angioid streaks”, still a pathognomonic clinical manifestation of
the disease. Finally, in 1929, Grönblad, an opthalmologist and Strandberg, a dermatologist, determined
that PXE was a specific entity. Currently, PXE diagnosis relies on the following criteria: clinically
suggestive skin lesions, angioid streaks, fragmented and calcified elastic fibers on skin biopsy [8].
The cardiovascular complications linked to PXE were initially reported by Balzer in 1884 who described
an “elastic degeneration of the skin and heart” and Carlsborg gave the first well-documented study
of cardiovascular elastic tissue calcification in 1944. Since that time, the term “pseudoxanthoma
elasticum” continues to be the most frequently used to designate this pathology in the literature for
historical reasons. However, one would suggest elasto-calcinosis as more appropriate [9].
3. Vascular Lesions of PXE
Beside the skin and retinal lesions, the arterial phenotype is an important aspect of the disease.
The internal elastic laminae in arteries are the most frequently affected. The small and medium
peripheral arterial beds are mostly involved [10], although other arteries, such as the coronary and the
cerebral arteries may also be affected. Typically, arterial lesions are characterized by an obstruction
of the lumen from a diffuse thickening of the wall and an echogenic plaque revealing calcification.
The lesions are primarily found on straight segments in leg arteries such as the superficialis femoralis
or arteries below knee. To date, the exact nature of these lesions is unknown in humans and lower limb
intermittent claudication due to peripheral occlusive disease represent a typical symptom of the disease
affecting more than 20% of the patients [11]. Contrary to what is expected with arterial mediacalcosis,
arterial compressibility is well-preserved in PXE, suggesting a specific arterial remodeling [11]. In fact,
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abnormal proteoglycan deposits, authenticated by post mortem histology, contributing to the arterial
obstruction was also advocated to preserve the compressibility of the peripheral arteries despite
fragmentation and calcifications of the elastin fibers [12,13]. To the best of our knowledge, medial
hyperplasia has never been reported in these patients. Arterial wall aneurysms have been described in
PXE patients, mostly in the intracranial vasculature and as an indirect consequence of the collateral
flow [14]. Although PXE patients are at high risk for stroke, it is mostly attributed to a small-cerebral
vessel disease with narrowed arteries rather than to embolisms. Increased myogenic tone in resistance
arteries, primarily evidenced in Abcc6−/− mice [15], may be responsible for such ischemic events,
even no evidence for such mechanisms have been shown in humans. Taken as a whole, the vascular
phenotype of PXE is unique and is not associated to bone mineralization defect [16] in contrast
with non-genetic vascular calcifying diseases, namely osteoporosis and/or chronic kidney disease
(CKD) [17].
Although arterial calcifications represent the most visible cardiovascular lesions in PXE,
other abnormalities have been reported [9]. Cardiac tissue may be affected in PXE. Some cohort studies
have reported specific changes in myocardial function whereas others reported that preclinical cardiac
dysfunction were rare [18,19]. Recently, results from prospective and comprehensive assessment of
cardiac function in 67 PXE patients aged 48 ± 15 years were found not to be different from those
of a comparable population regarding coronary artery disease, valve disease and echocardiography
findings [20].
4. Lessons Learned from Knockout Mice
Knockout animal models mimicking PXE disease have been developed using targeted disruption
of selected exons in Abcc6 [21,22]. These models replicate the human phenotype with mouse-specific
distinctions. For example, Abcc6−/− mice lack skin lesions but exhibit abnormal calcification of the
capsule of the vibrissae, a connective tissue absent in humans [21]. These knockout mice also mimic
the human cardiovascular phenotype [21,23] including higher intima-media thickness [24]. A higher
myogenic tone in distal arteries has been also observed [15], which has not been reported yet in
PXE patients. Finally, cardiac hypertrophy was described in Abcc6−/− mice after 24 months of life,
suggesting that late cardiomyopathy could develop in older PXE patients [20]. Abcc6 deficiency was
recently linked to an acute cardiac calcification phenotype referred to as dystrophic cardiac calcification
(DCC) in several inbred strains of mice including C3H/HeJ and DBA/2J [25–29]. DCC is an autosomal
recessive trait that was described several decades ago [27,29] in mice but not in humans to our
knowledge. It is a spontaneous condition affecting cardiovascular tissues that can also be triggered
into an acute phenotype by specific diet or direct injury causing myocardia necrotic lesions [27,29].
The Dyscalc1 locus affecting DCC was mapped to chromosome 7 [30–32] and a single Abcc6 gene
mutation leads to a constitutive decrease in protein levels in the liver [25,28]. Additional loci affecting
the penetrance and expression of the DCC phenotype were mapped to chromosomes 4, 12, and 14 [31].
Other knock out models have been engineered in rats [33] and zebrafish [34] showing the importance
of the Abcc6 gene in the calcifying phenotype of vertebrae.
5. Molecular Aspects of ABCC6
In 2000, Le Saux et al. identified the first PXE-causing mutations in the gene encoding ABCC6
(also referred to as multi-drug resistance-associated protein-6, MRP6) [35]. Genetic linkage analysis
failed to reveal any locus heterogeneity, suggesting that ABCC6 is solely responsible for PXE.
Today, more than 300 mutations have been identified (Table 1 and Figure 1). The vast majority is
represented by single nucleotide substitutions resulting in missense, nonsense and splice variants while
a few others are large and small deletions or insertions [36]. The ABCC6 gene is a member of the gene
family encoding ATP-binding cassette (ABC) proteins, one of the largest gene families. The 48 human
ABC transporters are distributed in 7 classes from A to G. All these genes code for proteins, which have
conserved domains specific to ATP binding and hydrolysis (e.g., Walker A, B and signature sequence).
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All ABC transporters are transmembrane proteins as their function mainly relate to the cellular efflux
of a variety of compounds. ABC transporters are composed of transmembrane domain (TMD) and
nucleotide binding domain (NBD). Two NDB domains interact to utilize ATP. The ABCC transporters
are divided into two subgroups based on their short or long structure. The long ABCC family members,
ABCC1, 2, 3, 6 and 10 contain a specific N-terminal TMD0 domain followed by an L0 linker segment
connecting to the transmembrane and NDB-1 and -2 regions. Genes coding for long ABCC proteins are
closely related to each other and are present in all eukaryotic kingdoms. They are likely to have evolved
from a distant ancestor by a series of gene duplication events [37]. The evolution of ABC transporters
is still ongoing. Indeed, the human ABCC6 underwent several recent partial gene duplications leading
to two pseudogenes and a third shorter fragment [38]. These pseudogenes appeared by similar
mechanisms in different primates but independently in humans and chimpanzee [37].
The transcriptional regulation of ABCC6 in human and mice has been investigated in detail.
Both activator and silencer elements have been identified in the promoter [39]. The core promoter
was mapped to the −145/+72 bp (numbering relative to the translational start site), which confers a
ubiquitous low expression in cell assay systems [39]. Two other activator sequences were identified
in the upstream promoter region: an evolutionarily highly conserved region between −209/−145 bp
and a stronger primate-specific region between −234 and −209 bp. Both of these elements confer
tissue-specific activity to the gene [40,41]. Furthermore, a strong primate-specific activator sequence was
identified in the first intron of the gene. This intronic sequence interacts with and its activity depends
on regulatory sequences of the promoter [42]. Several transcription factors playing an important
role in the regulation of ABCC6 expression were identified. The most important among them is
hepatocyte nuclear factor 4α (HNF4α), which binds to the evolutionarily highly conserved element of
the promoter [40–42]. HNF4α plays a particularly important role in the maintenance of homeostasis
of hepatocytes by regulating the expression of more than 1000 genes. This nuclear receptor seems to
be a major determinant of tissue-specificity for ABCC6 as this gene is highly expressed in tissues and
cells in which HNF4α is present. In another set of experiments the sensitivity of ABCC6 expression to
environmental stimuli has been demonstrated and the molecular mechanisms of the alteration of gene
expression level was also elucidated in some cases. The expression level of the gene is down regulated by
growth factors (hepatocyte growth factor, epidermal growth factor and potentially transforming growth
factor-β, although the latter is controversial) [40,43] and oxidative stress. Several studies have shown
the inhibitory effect of oxidative stress on ABCC6 expression [12,40], which led to the hypothesis that,
this could contribute to development of PXE-like manifestations in beta-thalassemia patients [44,45].
It has been shown that these effects, in part converge on the ERK1/2 pathway, which upon activation
phosphorylates HNF4α leading to the reduced binding of the factor to its response element in the
promoter [46]. This may then cause the repression of ABCC6 expression. Similarly, other environmental
stimuli activating protein kinase cascades (PKA, PKC and AMPK) lead to the reduced activity of
HNF4α and the decreased expression of ABCC6. ABCC6 was reported to be capable to transport
leukotriene C4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS) in vitro [47].
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Table 1. Summary of PXE-associated ABCC6 mutations.
Sequence Variations
at Protein Level Transport Activity
Wild-Type-Like
Localization
Mutations Responding
to 4-PBA References
p.R1114P Yes No Yes [48,49]
p.S1121W Yes No Yes [48,49]
p.R1138Q Yes No No [48,50]
p.V1298F No Yes Nd [47,50]
p.T1301I Yes No No [48]
p.G1302R No Nd Nd [47]
p.R1314W Yes No Yes [47–49]
p.G1321S No No Nd [47,48,50]
p.R1339C Nd Not stable No [48,50]
p.Q1347H Yes No Yes [48,49]
p.R1459C Yes Yes Nd [48]
Summary of experimental evidences on the activity, localization and rescue of PXE-associated ABCC6 mutations.
In vitro and in vivo characterization of the given variants as well as rescue experiments of membrane trafficking
deficient variants with the chemical chaperon molecule 4-phenylbutirate (4-PBA) is described in details within the
listed articles. Nd: not determined. More information is available in Table S1.
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Figure 1. Topology model illustrating the distribution of PXE-associated missense mutations in the
ABCC6 protein. Legend: nucleotidE binding domains and the transmembrane helices are shown
in grey. Missense mutations are represented in red. The transmembrane domains (TMD0, TMD1,
and TMD2) and the linker regions (L0, L1) of the protein are indicated.
6. Pathophysiology of ABCC6
The expression pattern of ABCC6 gene has been extensively studied. ABCC6 is primarily expressed
in the liver [51–55], with moderate levels in the proximal tubules of the kidneys [56,57] and has also
been detected in the intestines [42,53]. While the expression level is considered to be low or absent in
other tissues, few studies reported ubiquitous presence of ABCC6 [52,58]. The paradox that ABCC6 is
almost entirely missing from tissues directly affected by ectopic mineralization in humans, mice and
rats [33,59,60] has led to the hypothesis that PXE could be due to a circulating factor [61]. Accordingly,
a systemic factor transported by ABCC6 into the circulation under physiological conditions, would
play a key role in preventing ectopic calcification. This hypothesis was supported by parabiotic
experiments using crosses of wild type and Abcc6−/− mice with Rag−/− immune-tolerant animals.
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Indeed, this study found that the calcifying phenotype of Abcc6−/− mice was inhibited when sharing
blood circulation with wild type animals, demonstrating the presence of an inhibitory molecule [62].
The observation of low levels of carboxylated anticalcifying factors in the blood of PXE and the
report of PXE phenocopy due to a defect in vitamin K dependent γ-glutamyl carboxylase (GGCX) in
humans [63], suggested a possible role for vitamin K in PXE. GGCX is required for the activation of
matrix gla protein (MGP) by γ-glutamyl carboxylation with vitamin K2 as a co-factor [64]. The initial
and intriguing hypothesis that ABCC6 could release vitamin K into the systemic circulation was rapidly
discounted when it was shown that the supplementation of vitamin K2 failed to ameliorate the PXE
phenotype in Abcc6−/− mice [65,66]. In 2014, Jansen et al. opened a new chapter in the pathophysiology
of PXE [62]. In two pivotal studies [67,68], these authors demonstrated that expression of ABCC6 in
HEK cells was linked to a higher release of ATP in the culture media. Interestingly, a link between
ABC transporters and extracellular levels of ATP is not new. Release of ATP has been also reported
with cystic fibrosis trans membrane conductance regulator (CFTR, alias ABCC7) and P-glycoprotein
(ABCB1) [69,70] suggesting at first that ABCC6 could extrude triphosphated compounds. In their
cellular models, Jansen et al. failed to show a direct ABCC6-mediated ATP transport in vitro [68].
The fact that ABCC6 is involved in a pathway of extracellular nucleotide metabolism appears of
paramount importance because it establishes a link between PXE and generalized arterial calcification
of infancy (GACI) [71] or calcification of joints and arteries (ACDC) [72]. Indeed, the clinical
manifestations linked to this pathway are substantial ectopic (cardiovascular) calcifications. The related
diseases are caused by mutations in ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)
and in ecto-5’-nucleotidase (NT5E, alias CD73), which encode proteins involved in extracellular ATP
and PPi metabolism (Table 2). This finding prompted the hypothesis that PXE patients could be
deficient in PPi, which is a potent anti-calcifying molecule resulting from the hydrolysis of extracellular
ATP [73]. Indeed, a 2.5 fold reduction of PPi levels in humans was observed in PXE patients
and in Abcc6−/− mice [67], whereas Enpp1−/− mice have very low PPi levels [74]. Further, the
cross-transplantation experiments between Enpp1−/− and wild type mice showed that aortas of
Enpp1−/− mice no longer showed calcification after transplantation into wild-type mice while allografts
of wild-type mice calcified in Enpp1−/− mice [74]. It is now a matter of fact, that Abcc6 deficiency
in both local and distant cells/tissues is necessary to achieve the early onset and penetrant ectopic
calcification observed in humans and mice [21]. Recently, Ziegler et al. showed that Abcc6 conditional
knockout in vascular endothelium, liver or the kidneys was not sufficient to promote calcification of
the capsule of the vibrissae in mice [75]. In contrast, deletion of Abcc6 in the liver led to mineralization
after a period of one year. Most of the systemic PPi (60%) is believed to be produced by the liver in an
ABCC6-dependent manner [33,67]. The fact that PPi levels only decrease after targeted disruption of
Abcc6 in the liver reinforces this hypothesis [75].
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Table 2. Overview of genetic calcifying diseases.
Human Disease Protein OMIM Localization of Symptomatic Calcifications Treatment
Pseudoxanthoma elasticum (PXE) ATP-binding cassette transporter, subfamily C,member 6 (ABCC6) 264800 Skin, arteries None
Craniometaphyseal dysplasia, autosomal dominant
(CMDD) or Chondrocalcinosis 2 (CCAL2)
Inorganic pyrophosphate transport
regulator (ANKH) 118600 or 123000 Cartilage (joints) None
Generalized arterial calcification in infancy (GACI) Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) 208000 Arteries Bisphoshonate
Arterial calcification due to deficiency of CD73 (ACDC) Ecto 5’ nucleotidase (NT5E) alias CD73 21288095 Arteries and distal joints None
Keutel syndrome Matrix Gla Protein (MGP) 245150 Cartilage (trachea, bronchiae, rib) None
Juvenil Paget Disease/Hyperostosis corticalis
deformans juvenilis Osteoprotegerin (OPG) 239000 Bone Bisphoshonate
Tumoral calcinosis, hyperphosphatemic
Klotho or fibroblast growth factor 23 (FGF23) or
polypeptide N-acetylgalactosaminyl-transferase 3
(GALNT3)
211900 Arteries None
Hutchinson–Gilford progeria syndrome (HGPS) Laminin A (LMNA) 176670 Arteries, aortic valves None
Fibrodysplasia ossificans progressiva (FOP) Activin A receptor type 1 (ACVR1) 135100 Skeletal muscle, fascia, tendons and ligaments
Glucocorticoids,
non-steroidal
anti-inflammatory drugs
Coeliac disease with epilepsy and
cerebral calcifications (CEC) Unknown 226810 Brain (occipital area) None
Idiopathic basal ganglia calcification (IBGC)
Sodium-dependent Pi co-transporter 2 (PiT-2) or
platelet derived growth factor (PDGF) or (platelet
derived growth factor receptor B) PDGFRB
158378 or 190040 or 173410 Brain (basal ganglia, thalamus, cerebellum) None
Int. J. Mol. Sci. 2017, 18, 1941 8 of 16
7. ABCC6 in the Context of Biomineralization
Inorganic pyrophosphate (PPi) is slightly absorbed by the intestinal epithelium [76]. Its normal
fasting plasma level in humans is 2–4 µmol/L and it mainly depends on a balance between its cellular
production and its hydrolysis [73]. PPi originates from the transport regulator protein encoded by
ANKH [77] and from ATP degradation by ENPP1, which converts ATP into AMP and PPi. Physiological
plasma levels of ATP are 0.02 to 0.2 µmol/L [78,79]. ATP, PPi and Pi are interdependent. PPi can be
hydrolysed into Pi by Tissue Non-specific Alkaline Phosphatase (TNAP). Of note, adenosine resulting
from the lysis of AMP by CD73 represses the expression of the gene encoding TNAP and is able to
increase PPi levels [75]. Therefore, PPi levels depend on a balance between its production through
ENPP1 and its degradation by the adenosine-regulated activity of TNAP. As a result, crossing Abcc6−/−
mice with Enpp1−/− mice did not increase calcifications of the capsule of the vibrissae as observed
in Enpp1−/− mice. In contrast, calcifications resulting from Abcc6 inactivation were augmented by
crossing Abcc6−/− mice with Nt5e−/− mice [75] and Abcc6−/− mice have reduced Nt5e expression in
their arteries [15]. It should be remembered that other molecular mechanisms are able to mediate ATP
release independently of ABCC6: vesicular exocytosis at nerve terminals, connexin hemichannel and
pannexin channel activity [80]. These mechanisms are important because low PPi plasma levels of
Abcc6−/− mice and PXE patients [67] indicates that 40% of PPi comes from an ABCC6-independent ATP
release. Despite overwhelming evidence linking PPi deficiency to the PXE phenotype, some concerns
remain. As a matter of fact, the overexpression of the human ENPP1 gene in Abcc6−/− mice led to
incomplete reduction in mineralization despite increased PPi levels, suggesting that ABCC6 drives
other cellular and/or molecular mechanisms resulting in the calcification phenotype in PXE [81].
8. A Role for ABCC6 into the Pathophysiology of Vascular Calcifications in Acquired
Metabolic Diseases?
Calcifications of the arterial media (also termed mediacalcosis) are common features of CKD and
osteoporosis. In contrast to PXE [16], mediacalcosis is linked to disturbed bone mineralization or bone
turnover leading to increased risk of fracture and to the “bone-arterial calcification paradox” [17].
Remarkably, patients suffering from CKD have an increased rate of fracture [82,83] and patients
affected by osteoporosis display more arterial calcifications [84] or develop them over time in parallel
to loss of their mineral bone mass [85]. More than 10% of the general population suffers from
CKD [86] and cardiovascular diseases represent the first cause of mortality in CKD [87,88] mostly
associated to arterial calcifications. Arterial calcifications in CKD are not limited to mediacalcosis
and atherosclerotic lesions are also present. A widely used marker of AC is the Agatston coronary
artery calcification (CAC) score, measured with electron-beam computer tomography [89], which does
not provide information on the spatial distribution of calcifications in the arterial wall (i.e., intimal
versus medial layer). However, CAC score is a strong independent risk factor of cardiovascular
mortality [90]. This score is remarkably high in CKD patients undergoing regular dialysis, even in
children and in adults under the age of 30 [91,92]. The role of ABCC6 in CKD has not been addressed
thoroughly yet. As a matter of fact, PPi/Pi ratio is low because Pi levels are high [93] and PPi levels
are low [94,95] at least in advanced CKD stages. The observation of a lower hepatic expression of
Abcc6 in uremic rats [96] suggests that decreased PPi level observed in CKD could be caused by a
decreased ATP-derived PPi production from the liver. TNAP react to uremic compounds because
exposure of rat aortic ring to uremic plasma increases arterial TNAP activity and because TNAP
expression increases in the arterial wall of the aorta of uremic rats following 5/6 nephrectomy [97].
This could lower local PPi level and favor AC [97]. Plasma TNAP activity is usually high in CKD
following increased bone remodeling, which mainly results from secondary hyperparathyroidism.
Remarkably, high TNAP activity is related to cardiovascular (CV) mortality in CKD after adjustment
for other usual risk factors [98]. TNAP-driven increased PPi hydrolysis could augment AC and offer
a rational explanation for this latter observation. Another frequent disease affecting 20% to 30 % of
the general population in Europe [99], which is associated with high level of AC is non-alcoholic
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fatty liver disease (NAFLD). Patients affected by NAFLD are at high risk for CAC independently
from diabetes, gender and age [100,101]. NALFD patients primarily die from CV diseases [102–104].
Liver fibrosis seems of particular relevance regarding CAC and CV mortality. Indeed, CAC score is
significantly higher in NAFLD patients with an intermediate to high fibrosis index than in those with a
low fibrosis index [105]. Furthermore, liver fibrosis is independently associated with CAC score in
NAFLD patients [106,107]. It has been reported that advanced fibrosis is also a significant predictor
of mortality from CV disease in NAFLD patients [108]. To our knowledge, expression of ABCC6 or
the PPi/Pi ratio have not been examined in patients with liver fibrosis. However, it has been shown
using liver 32P-NTP magnetic resonance imaging (MRI) that hepatic mitochondrial ATP homeostasis
was impaired in patients with NAFLD [109,110]. Therefore, one might speculate that decreased ATP
production from the liver could lower ABCC6-mediated extracellular ATP release and in turn reduce
systemic PPi levels, which may provide an explanation for increased AC in NAFLD patients.
9. Therapeutic Perspectives
To date an etiologic treatment of the ABCC6 deficiency is still lacking. Therapeutics should aim
at preventing hydroxyapatite deposits by increasing PPi plasma levels and/or at drawing calcium
out of the calcifying lesions by lowering Pi levels. Phosphate binders are commonly used in CKD
to lower Pi levels. They have been proposed for the treatment of PXE following a successful pilot
study with aluminum hydroxide in humans [111]. However, a randomized controlled trial performed
with sevelamer hydrochloride showed no improvement [112]. This unexpected result was attributed
to the high magnesium (Mg) content in the placebo controls. Dietary supplementation with Mg in
Abcc6−/− mice was shown to contribute to reduce calcifications but the Mg concentrations used were
more elevated than acceptable for human use [113]. Pharmacologic blockade of TNAP could be a
valuable tool for limiting AC as this enzyme promotes the hydrolysis of PPi. However, the risk of bone
demineralization, which is exemplified by the patients suffering from hypophosphatasia, may be a
limitation [98]. PPi administration has been considered for the treatment of AC. Daily intraperitoneal
injection almost completely inhibited calcification in Abcc6−/− mice [114] and reduced the calcium
content of the arterial wall of uremic rats without affecting bone mineralization [115]. Although
originally thought to be completely hydrolyzed within the guts, oral gavage of mice with PPi was
shown to significantly reduce calcification both in Abcc6−/− and Enpp1−/− mice [76]. Restoration
of Abcc6 function with chemical chaperone 4-phenylbutyrate treatment in case of localization
deficient disease caused by Abcc6 mutants was also shown to be effective by rescuing injury-induced
dystrophic cardiac calcifications [48,49]. Some bisphosphonate, non-hydrolysable analogs of PPi,
prevent vascular calcifications induced by excess Vitamin D in rats [116] and reduce ectopic calcification
in Abcc6−/− mice [117]. Soluble forms of ENPP1 where proposed as treatment to increase circulating
PPi. Such treatment displayed efficacy to prevent calcification in Enpp1−/− mice [118] and could
theoretically be used in the context of ABCC6 deficiency. Finally, experimental data reported that
vitamin K intake could improve soft tissue’s ectopic calcifications such as those induced by the use of
anti-vitamin K drugs [119,120]. However, the addition of vitamin K2 to the diet of Abcc6−/− mice did
not significantly improved calcifications [65,66].
10. Conclusions
In conclusion, current results suggest that ABCC6-dependent plasmatic PPi levels are the
major determinant of soft tissue mineralization in PXE, but also hint at a PPi independent
unknown mechanism, by which ABCC6 prevents ectopic mineralization under physiologic conditions.
ABCC6 involvement in the metabolism of the extracellular nucleotides, which play a central role for
cellular energy, autocrine/paracrine and possibly remote signalizations, points to a possible role of
purinergic signaling in the development of arterial calcifications in PXE patients. The understanding
of the bio-mineralization process based on rare monogenic calcifying diseases sheds light on arterial
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calcifications and high cardiovascular mortality of CKD and NAFLD, which are far more frequent
diseases, and could pave the way for therapeutic solutions.
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